Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Researchers find new benefits, risks in GLP-1 weight loss drugs (opens in a new tab)

wafb.com · 2026-08-18

Short answerEvidenceSource

Short answer

Several possible studies

No confirmed study match.

Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

The literature search

16 candidate papers

Papers surfaced in our search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 6Not checkedResearchers say some GLP-1 drug benefits have been surprising, including a reported decrease in desire to drink alcohol and improved arthritis symptoms.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 6Not checkedHeymsfield said studies have shown GLP-1 drugs reduced the risks of heart attacks, cardiovascular disease, and mortality, and may improve inflammation in ways that help the heart.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 6Not checkedHeymsfield said some patients on GLP-1 drugs do not eat adequately and have developed vitamin deficiencies, including scurvy from vitamin C deficiency.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 6Not checkedThe article says muscle and bone loss are concerns for people losing weight on GLP-1 drugs, especially frail patients, and researchers are studying ways to reduce that loss.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 6Not checkedHeymsfield said retatrutide, a triple agonist drug acting on GLP-1, GIP and glucagon, has produced the most weight loss seen so far in this class, around 25% to 30%, but with more side effects and it is still in phase three trials.View evidenceHide evidence

As stated25% to 30%

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 6Not checkedHe said GLP-1 drugs are safe when taken as prescribed, but their effects stop after discontinuation unless lasting diet-and-exercise changes were made, and weight cycling is common.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Explore all search results